Palumbo Wealth Management LLC Takes $2.41 Million Position in Boston Scientific Corporation $BSX

Palumbo Wealth Management LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 25,330 shares of the medical equipment provider’s stock, valued at approximately $2,405,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BSX. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares in the last quarter. State Street Corp increased its holdings in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Synergy Asset Management LLC increased its holdings in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after buying an additional 14,700 shares during the last quarter. Finally, Channel Wealth LLC lifted its holdings in Boston Scientific by 70.8% during the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after buying an additional 11,847 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $74.37 on Tuesday. The company has a 50-day moving average price of $88.87 and a two-hundred day moving average price of $96.32. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50. The stock has a market cap of $110.36 billion, a price-to-earnings ratio of 38.33, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the firm posted $0.70 earnings per share. The business’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Needham & Company LLC dropped their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Robert W. Baird dropped their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Morgan Stanley reduced their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Truist Financial lowered their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Finally, Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.